Novo Nordisk A/S has stated its aim to be a leader in the RNAi therapeutic space by agreeing to pay $3.3bn to acquire Dicerna Pharmaceuticals, Inc., a company it has been collaborating with for the past two years.
RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna
Paying $3.3bn
The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.
More from Deals
More from Business
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.